Home Newsfeeds BMO Capital Downgrades Horizon Therapeutics to Market Perform

BMO Capital Downgrades Horizon Therapeutics to Market Perform

BMO Capital analyst Gary Nachman downgrades Horizon Therapeutics (NASDAQ:HZNP) from Outperform to Market Perform.

byBenzinga Newsdesk

December 13, 2022

1 minute read

BMO Capital analyst Gary Nachman downgrades Horizon Therapeutics (NASDAQ:HZNP) from Outperform to Market Perform.

JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $327

By Benzinga Newsdesk

October 24, 10:42 AM

JP Morgan analyst Jessica Fye maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $319 to $327.

VRTX

General Dynamics Bags ~$273M US Navy Contract

By Akanksha Bakshi

July 20, 12:48 PM

General Dynamics Corp (NYSE:GD) business unit General Dynamics Mission Systems has secured a $272.9 million U.S. Navy contract to support the…

UBS Initiates Coverage On Calumet Specialty with Neutral Rating, Announces Price Target of $15.7

By Benzinga Newsdesk

December 14, 10:16 AM

UBS analyst Manav Gupta initiates coverage on Calumet Specialty (NASDAQ:CLMT) with a Neutral rating and announces Price Target of $15.7.

CLMT

News

Desktop Health Announces Flexcera Base Ultra+ Dental Resin For Stronger, More Comfortable 3D Printed Dentures

By Benzinga Newsdesk

February 12, 9:10 AM

Flexcera Base Ultra+ is a 3D printable, light-curable resin used for the fabrication of the gingiva component of full and partial removable dentures3D printing Flexcera Base Ultra+ helps dentists and dental labs reduce

BMO Capital Downgrades Horizon Therapeutics to Market Perform

Related Posts

JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $327

General Dynamics Bags ~$273M US Navy Contract

UBS Initiates Coverage On Calumet Specialty with Neutral Rating, Announces Price Target of $15.7

Desktop Health Announces Flexcera Base Ultra+ Dental Resin For Stronger, More Comfortable 3D Printed Dentures